Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 12, 2009, Pages 1601-1608

  Klettner, Alexa Karina ^a   Kruse, Marie Luise ^a   Meyer, Tim ^a   Wesch, Daniela ^a   Kabelitz, Dieter ^a   Roider, Johann ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Age related macular degeneration (AMD); Bevacizumab; Ranibizumab; VEGF antagonists

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL DEATH; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN SECRETION; SWINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL SURVIVAL; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MICROSCOPY, CONFOCAL; ORGAN CULTURE TECHNIQUES; RETINAL PIGMENT EPITHELIUM; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71449092758     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1136-0     Document Type: Article

References (21)

1. KJ Kim B Li K Houck J Winer N Ferrara 1992 The VEGF proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies Growth Factors 7 53 64 10.3109/08977199209023937 1:STN:280: DyaK38zmvVKmtg%3D%3D 1380254
2. I Krämer HP Lipp 2007 Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer J Clin Pharm Ther 32 1 14 10.1111/j.1365-2710.2007.00800.x 17286784 (Pubitemid 46213936)
3. N Ferrara L Damico N Shams H Lowman R Kim 2006 Development of ranibizumab, an anti-VEGF antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 859 870 10.1097/01.iae.0000242842. 14624.e7 17031284 (Pubitemid 44547437)
4. J Mordenti RA Cuthbertson N Ferrara K Thomsen L Berleau V Licko PC Allen CR Valverde YG Meng DT Fei KM Fourre AM Ryan 1999 Comparison of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration Toxicol Pharmacol 27 536 544 1:CAS:528:DyaK1MXmsFyntLo%3D
5. P Heiduschka H Fietz S Hofmeister S Schultheiss AF Mack S Peters F Ziemssen B Niggemann S Julien KU Bartz-Schmidt U Schraermeyer 2007 Penetration of bevacizumab through the retina after intravitreal injection in the monkey Invest Ophthalmol Vis Sci 48 2814 2823 10.1167/iovs.06-1171 17525217 (Pubitemid 351261238)
6. S Michels PJ Rosenfeld CA Puliafito EN Marcus AS Venkatraman 2005 Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study Ophthalmology 112 1035 1047 10.1016/j.ophtha.2005.02.007 15936441 (Pubitemid 40797459)
7. SS Lynch CM Cheng 2007 Bevacizumab for neovascular ocular disease Ann Pharmacother 41 614 625 10.1345/aph.1H316 1:CAS:528:DC%2BD2sXltlOnsrs%3D 17355998 (Pubitemid 46625484)
8. S Mennel J Callizo JC Schmidt CH Meyer 2007 Acute retinal pigment epithelial tear in the untreated eye following repeated bevacizumab (Avastin) injections Acta Ophthalmol Scand 85 689 691 10.1111/j.1600-0420.2007.00926.x 17403025 (Pubitemid 47316777)
9. S Peters P Heiduschka S Julien S Grisanti F Ziemssen M Adler U Schraermeyer KU Bartz-Schmidt 2007 Ultrastructural findings in the primate eye after intravitreal injections of bevacizumab Am J Ophthalmol 143 995 1002 10.1016/j.ajo.2007.03.007 1:CAS:528:DC%2BD2sXlvVakur4%3D 17449002 (Pubitemid 46764670)
10. European Medicines Agency, European Public Assessment Report (EPAR) on Avastin, Scientific Discussion, 2005, pp 1-61
11. A Klettner J Roider 2008 Comparison of Bevacizumab, Ranibizumab and Pegaptanib in vitro: efficiency and possible additional pathways Invest Ophthalmol Vis Sci 49 4523 4527 10.1167/iovs.08-2055 18441313
12. MS Spitzer E Yoeruek A Sierra B Wallenfels U Schraermeyer B Spitzer KU Bartz-Schmidt P Szurman 2007 Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells Graefes Arch Clin Exp Ophthalmol 245 1837 1842 10.1007/s00417-007-0568-7 1:CAS:528:DC%2BD2sXhtlWrtrrN 17347807 (Pubitemid 350154019)
13. RL Avery DJ Pieramici MD Rabena AA Castellarin MA Nasir MJ Giust 2006 Intravitreal Bevacizumab (Avastin) for neovascular AMD Ophthalmology 113 363 372 10.1016/j.ophtha.2005.11.019 16458968 (Pubitemid 43296975)
14. F Gelisken F Ziemssen M Voelker KU Bartz-Schmidt 2006 Retinal pigment epithelial tear following Bevacizumab injection for neovascular age-related macular degeneration Acta Ophthalm Scand 84 833 834 10.1111/j.1600-0420.2006. 00765.x (Pubitemid 44688343)
15. A Chiang LK Chang F Yu D Sarraf 2008 Predictors of anti-VEGF associated retinal pigment epithelial tear using FA and OCT analysis Retina 28 1265 1269 10.1097/IAE.0b013e31817d5d03 18628724
16. M Raghavan PJ Bjorkman 1996 Fc Receptors and their interaction with immunoglobins Annu Rev Cell Dev Biol 12 181 220 10.1146/annurev.cellbio.12.1.181 1:CAS:528:DyaK28XnsFClsr0%3D 8970726 (Pubitemid 26422713)
17. CD Eckhert DB Hafeman 1986 Search for Fc and C3b receptors on black-eyed RCS rat RPE cells Curr Eye Res 5 911 917 10.3109/02713688608995171 1:CAS:528:DyaL1cXhs1Grsbw%3D 2948775
18. VM Elner T Schaffner K Tayler S Glagov 1981 Immunophagocytic properties of retinal pigment epithelium cells Science 211 74 76 10.1126/science.7444450 1:STN:280:DyaL3M%2FnvVOlsw%3D%3D 7444450
19. BI Tarnowski VL Shepherd BJ McLaughlin 1988 Expression of mannose receptors for pinocytosis and phagocytosis on RPE Invest Ophthalmol Vis Sci 29 742 748 1:CAS:528:DyaL1cXksFalsbk%3D 3366565
20. CS Alge SG Priglinger D Kook H Schmid C Haritoglou U Welge-Lussen A Kampik 2006 Galectin-1 influences migration of retinal pigment epithelial cells Invest Ophthalmol Vis Sci 47 415 426 10.1167/iovs.05-0308 16384992 (Pubitemid 46780843)
21. E An X Lu J Flippin JM Devaney B Halligan EP Hoffman N Strunnikova K Csaky Y Hathout 2006 Secreted proteome profiling in human RPE cell cultures derived from donors with age-related macular degeneration and age-matched donors J Proteome Res 5 2599 2610 10.1021/pr060121j 1:CAS:528:DC%2BD28XosVSmtLc%3D 17022631 (Pubitemid 44595162)